Cargando…
A novel diagnostic four-gene signature for hepatocellular carcinoma based on artificial neural network: Development, validation, and drug screening
Background: Hepatocellular carcinoma (HCC) is one of the most common cancers with high mortality in the world. HCC screening and diagnostic models are becoming effective strategies to reduce mortality and improve the overall survival (OS) of patients. Here, we expected to establish an effective nove...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9554094/ https://www.ncbi.nlm.nih.gov/pubmed/36246599 http://dx.doi.org/10.3389/fgene.2022.942166 |
_version_ | 1784806617262325760 |
---|---|
author | Chen, Min Wu, Guang-Bo Xie, Zhi-Wen Shi, Dan-Li Luo, Meng |
author_facet | Chen, Min Wu, Guang-Bo Xie, Zhi-Wen Shi, Dan-Li Luo, Meng |
author_sort | Chen, Min |
collection | PubMed |
description | Background: Hepatocellular carcinoma (HCC) is one of the most common cancers with high mortality in the world. HCC screening and diagnostic models are becoming effective strategies to reduce mortality and improve the overall survival (OS) of patients. Here, we expected to establish an effective novel diagnostic model based on new genes and explore potential drugs for HCC therapy. Methods: The gene expression data of HCC and normal samples (GSE14811, GSE60502, GSE84402, GSE101685, GSE102079, GSE113996, and GSE45436) were downloaded from the Gene Expression Omnibus (GEO) dataset. Bioinformatics analysis was performed to distinguish two differentially expressed genes (DEGs), diagnostic candidate genes, and functional enrichment pathways. QRT-PCR was used to validate the expression of diagnostic candidate genes. A diagnostic model based on candidate genes was established by an artificial neural network (ANN). Drug sensitivity analysis was used to explore potential drugs for HCC. CCK-8 assay was used to detect the viability of HepG2 under various presentative chemotherapy drugs. Results: There were 82 DEGs in cancer tissues compared to normal tissue. Protein–protein interaction (PPI), Gene Ontology (GO), and Kyoto Encyclopedia of Genes and Genomes (KEGG) enrichment analyses and infiltrating immune cell analysis were administered and analyzed. Diagnostic-related genes of MT1M, SPINK1, AKR1B10, and SLCO1B3 were selected from DEGs and used to construct a diagnostic model. The receiver operating characteristic (ROC) curves were 0.910 and 0.953 in the training and testing cohorts, respectively. Potential drugs, including vemurafenib, LOXO-101, dabrafenib, selumetinib, Arry-162, and NMS-E628, were found as well. Vemurafenib, dabrafenib, and selumetinib were observed to significantly affect HepG2 cell viability. Conclusion: The diagnostic model based on the four diagnostic-related genes by the ANN could provide predictive significance for diagnosis of HCC patients, which would be worthy of clinical application. Also, potential chemotherapy drugs might be effective for HCC therapy. |
format | Online Article Text |
id | pubmed-9554094 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-95540942022-10-13 A novel diagnostic four-gene signature for hepatocellular carcinoma based on artificial neural network: Development, validation, and drug screening Chen, Min Wu, Guang-Bo Xie, Zhi-Wen Shi, Dan-Li Luo, Meng Front Genet Genetics Background: Hepatocellular carcinoma (HCC) is one of the most common cancers with high mortality in the world. HCC screening and diagnostic models are becoming effective strategies to reduce mortality and improve the overall survival (OS) of patients. Here, we expected to establish an effective novel diagnostic model based on new genes and explore potential drugs for HCC therapy. Methods: The gene expression data of HCC and normal samples (GSE14811, GSE60502, GSE84402, GSE101685, GSE102079, GSE113996, and GSE45436) were downloaded from the Gene Expression Omnibus (GEO) dataset. Bioinformatics analysis was performed to distinguish two differentially expressed genes (DEGs), diagnostic candidate genes, and functional enrichment pathways. QRT-PCR was used to validate the expression of diagnostic candidate genes. A diagnostic model based on candidate genes was established by an artificial neural network (ANN). Drug sensitivity analysis was used to explore potential drugs for HCC. CCK-8 assay was used to detect the viability of HepG2 under various presentative chemotherapy drugs. Results: There were 82 DEGs in cancer tissues compared to normal tissue. Protein–protein interaction (PPI), Gene Ontology (GO), and Kyoto Encyclopedia of Genes and Genomes (KEGG) enrichment analyses and infiltrating immune cell analysis were administered and analyzed. Diagnostic-related genes of MT1M, SPINK1, AKR1B10, and SLCO1B3 were selected from DEGs and used to construct a diagnostic model. The receiver operating characteristic (ROC) curves were 0.910 and 0.953 in the training and testing cohorts, respectively. Potential drugs, including vemurafenib, LOXO-101, dabrafenib, selumetinib, Arry-162, and NMS-E628, were found as well. Vemurafenib, dabrafenib, and selumetinib were observed to significantly affect HepG2 cell viability. Conclusion: The diagnostic model based on the four diagnostic-related genes by the ANN could provide predictive significance for diagnosis of HCC patients, which would be worthy of clinical application. Also, potential chemotherapy drugs might be effective for HCC therapy. Frontiers Media S.A. 2022-09-28 /pmc/articles/PMC9554094/ /pubmed/36246599 http://dx.doi.org/10.3389/fgene.2022.942166 Text en Copyright © 2022 Chen, Wu, Xie, Shi and Luo. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Genetics Chen, Min Wu, Guang-Bo Xie, Zhi-Wen Shi, Dan-Li Luo, Meng A novel diagnostic four-gene signature for hepatocellular carcinoma based on artificial neural network: Development, validation, and drug screening |
title | A novel diagnostic four-gene signature for hepatocellular carcinoma based on artificial neural network: Development, validation, and drug screening |
title_full | A novel diagnostic four-gene signature for hepatocellular carcinoma based on artificial neural network: Development, validation, and drug screening |
title_fullStr | A novel diagnostic four-gene signature for hepatocellular carcinoma based on artificial neural network: Development, validation, and drug screening |
title_full_unstemmed | A novel diagnostic four-gene signature for hepatocellular carcinoma based on artificial neural network: Development, validation, and drug screening |
title_short | A novel diagnostic four-gene signature for hepatocellular carcinoma based on artificial neural network: Development, validation, and drug screening |
title_sort | novel diagnostic four-gene signature for hepatocellular carcinoma based on artificial neural network: development, validation, and drug screening |
topic | Genetics |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9554094/ https://www.ncbi.nlm.nih.gov/pubmed/36246599 http://dx.doi.org/10.3389/fgene.2022.942166 |
work_keys_str_mv | AT chenmin anoveldiagnosticfourgenesignatureforhepatocellularcarcinomabasedonartificialneuralnetworkdevelopmentvalidationanddrugscreening AT wuguangbo anoveldiagnosticfourgenesignatureforhepatocellularcarcinomabasedonartificialneuralnetworkdevelopmentvalidationanddrugscreening AT xiezhiwen anoveldiagnosticfourgenesignatureforhepatocellularcarcinomabasedonartificialneuralnetworkdevelopmentvalidationanddrugscreening AT shidanli anoveldiagnosticfourgenesignatureforhepatocellularcarcinomabasedonartificialneuralnetworkdevelopmentvalidationanddrugscreening AT luomeng anoveldiagnosticfourgenesignatureforhepatocellularcarcinomabasedonartificialneuralnetworkdevelopmentvalidationanddrugscreening AT chenmin noveldiagnosticfourgenesignatureforhepatocellularcarcinomabasedonartificialneuralnetworkdevelopmentvalidationanddrugscreening AT wuguangbo noveldiagnosticfourgenesignatureforhepatocellularcarcinomabasedonartificialneuralnetworkdevelopmentvalidationanddrugscreening AT xiezhiwen noveldiagnosticfourgenesignatureforhepatocellularcarcinomabasedonartificialneuralnetworkdevelopmentvalidationanddrugscreening AT shidanli noveldiagnosticfourgenesignatureforhepatocellularcarcinomabasedonartificialneuralnetworkdevelopmentvalidationanddrugscreening AT luomeng noveldiagnosticfourgenesignatureforhepatocellularcarcinomabasedonartificialneuralnetworkdevelopmentvalidationanddrugscreening |